KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Expenses: 2009-2024

Historic Operating Expenses for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $155.1 million.

  • Rigel Pharmaceuticals' Operating Expenses fell 0.51% to $41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.1 million, marking a year-over-year increase of 10.24%. This contributed to the annual value of $155.1 million for FY2024, which is 12.89% up from last year.
  • According to the latest figures from FY2024, Rigel Pharmaceuticals' Operating Expenses is $155.1 million, which was up 12.89% from $137.4 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Operating Expenses registered a high of $175.8 million during FY2022, and its lowest value of $137.4 million during FY2023.
  • Moreover, its 3-year median value for Operating Expenses was $155.1 million (2024), whereas its average is $156.1 million.
  • In the last 5 years, Rigel Pharmaceuticals' Operating Expenses rose by 17.54% in 2021 and then declined by 21.85% in 2023.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Operating Expenses stood at $137.6 million in 2020, then increased by 17.54% to $161.7 million in 2021, then grew by 8.69% to $175.8 million in 2022, then decreased by 21.85% to $137.4 million in 2023, then increased by 12.89% to $155.1 million in 2024.